Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Articles|October 11, 2021
- MHE October 2021
- Volume 31
- Issue 10
Foluso Agboola of ICER Looks to Her Mom for Teaching Her to Never Quit and Give Her Best at What She Puts Her Hands to
Author(s)Briana Contreras, Peter Wehrwein
In this video series, Agboola addresses two questions asked in the annual Emerging Health Leaders series: Which career accomplishment has given you the greatest satisfaction? and who has had the greatest influence on your life?
Advertisement
Articles in this issue
almost 5 years ago
Emerging Health Leaders: Sonia Samagh of Stealth Venturealmost 5 years ago
Emerging Health Leaders: Andrew Toy, M.S., of Clover Healthalmost 5 years ago
Emerging Health Leaders: Evie Powell, Ph.D., of Proprioalmost 5 years ago
Emerging Health Leaders: Michael Palantoni of AthenahealthAdvertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
5